Blind AI readers forecast four pending Federal Circuit appeals, including Samsung v. ITC and Taylor Made v. Costco, after a ...

I started pulling at a loose bristle this week and ended up doing a deep dive into the history of the American toothbrush. I came across a Library of Congress explanation that H.N. Wadsworth of ...

In December 2025, Director Squires invited applicants to begin filing special Rule 132 declarations focused on patent eligibility. He called these Subject Matter Eligibility Declarations, or SMEDs.

USPTO and IU Maurer announce a Spring 2027 PTAB Law School Moot Court Competition: one brief, APJ panels, and an in-person final in Alexandria.

Back in May 2026, I wrote that Williamson found its mark. After the Federal Circuit’s 2015 en banc decision, functional claims that rely upon a function coupled with a generic noun such as “module” or ...

Can a patentee rely on the presumption of validity when filing suit, even after the PTO has rejected closely related claims as ineligible? In Epic Tech, LLC v. Pen-Tech Associates, Inc., No. 2025-1624 ...

This post updates my September 21, 2026 post on FY2026 utility grants that was projecting out to end of the FY. The year is now over. I have also added two new cuts of the data: published applications ...

AIA has overstepped its boundaries on constitutional grounds as patents are private rights. All patent owners are entitled to ...

Best Practices: With the compressed issuance timeline, a growing number of patent practitioners are moving to a standard ...

The Third Circuit has affirmed partial summary judgment that ROSS Intelligence infringed Thomson Reuters's copyrights when it used Westlaw headnotes to train a competing AI legal search tool. Thomson ...

The Federal Circuit has affirmed invalidity of Satius's wireless-coupler patent, but on a different ground than the district court. Satius Holding, LLC v. Samsung Electronics Co., No. 2025-1446 (Fed.

The Federal Circuit has denied rehearing en banc in Teva v. Eli Lilly, leaving in place Judge Prost's April decision reinstating Teva's $177 million jury verdict against Lilly over its migraine drug ...